CRL

Business profile & competitive position

Charles River Laboratories International, Inc. sits in the Healthcare sector under the Medical - Diagnostics & Research industry. Its economic role is to provide outsourced research, testing, and laboratory services that support drug discovery, preclinical development, safety assessment, and related diagnostic workflows for pharmaceutical, biotechnology, and academic clients. In plain terms, CRL is a contract-research layer in the healthcare value chain, and its top line is tightly linked to how much outside R&D spending is flowing into early-stage science.

The current margin and return figures, however, cast doubt on how well that strategic position is translating into durable economics. Net margin is -6.0% and ROE is -7.7%. A negative return on equity of that size means the company is currently destroying shareholder value rather than compounding it, which implies that the regulatory accreditations, long-term client relationships, and specialized facilities normally viewed as a research-services moat are not generating profits above the cost of capital right now. The $12.9 billion market capitalization still embeds a recovery thesis, but the most recent profitability profile is what you would expect from a business whose utilization or pricing power is under pressure, not from one comfortably defended by a wide competitive moat.

Financial posture

CRL currently trades at a trailing P/E of -55.3, a number that is negative because the net margin is -6.0%. With the stock at $267.49 and a market cap of $12.9 billion, the valuation is being set by expectations rather than by current earnings power, so traditional P/E-based comparisons are effectively unusable until the bottom line turns positive. A beta of 1.40 signals that the stock has historically moved roughly 40% more than the broad market, a level consistent with a loss-making, research-cycle-sensitive name that reacts sharply to changes in biopharma funding sentiment and interest-rate expectations.

Profitability, not valuation multiples, is therefore the central issue. Negative ROE of -7.7% reinforces the negative margin message: the firm is not only failing to convert revenue into net income, it is also failing to cover its cost of equity. At the same time, the current snapshot shows an RSI of 76.2 and a price that sits roughly $49.80, or about 22.9%, above the 50-day EMA of $217.69. That tells you recent price momentum has run well ahead of the fundamental earnings profile captured in the latest reported figures.

Macro & geopolitical exposure

The Medical - Diagnostics & Research classification exposes CRL to a distinctive set of macro forces. Public research budgets—especially NIH funding in the United States and equivalent agencies abroad—feed directly into outsourced discovery and safety-testing demand. Any meaningful shift in government appropriations, reimbursement rules, or grant priorities can ripple through order flow faster than it would for a traditional pharmaceutical manufacturer.

Trade policy matters as well. Specialized reagents, laboratory instruments, and research consumables often cross borders multiple times during a study; tariffs, export controls, or customs delays raise input costs and can threaten study timelines. Currency exposure is another standard risk for an international research organization, because contracts may be denominated in euros, pounds, yen, or dollars while local operating costs are fixed in those same currencies. The sector is also tied to the biotech funding cycle: when venture capital and public-market financing for early-stage drug developers tighten, preclinical research outsourcing is frequently one of the first budget lines cut. Finally, diagnostic and research services face long-run regulatory risk; changes to FDA, EMA, or EPA guidelines can alter the volume and type of testing required, which helps or hurts revenue depending on the direction of the change.

Recent developments

The most recent news cluster centers on CRL's second-quarter 2026 results, reported on August 5, 2026. Seeking Alpha published the Q2 2026 earnings call transcript that day, and Zacks reported the same day that CRL's Q2 earnings and revenues beat expectations while full-year 2026 guidance was raised, sending the stock up in pre-market trading. The underlying numbers support that headline: actual EPS came in at $3.02 versus an estimate of $2.77, producing a 9% positive surprise, and the stock moved +1.84% in the next session.

On August 6, 2026, two additional items appeared. MarketBeat published Q2 earnings call highlights, and 247wallst.com included Charles River in its daily roundup, "Here Are Thursday’s Top Wall Street Analyst Research Calls: AppLovin, Charles River, Global Payments, HubSpot, Insulet Corporation, Roper Technologies, Sabra Health Care, Western Digital, Zillow Group, and More." Taken together, the August 5-6 coverage suggests Wall Street was digesting a beat-and-raise quarter, even though the headline stock reaction was modest relative to the magnitude of the EPS beat.

Earnings behavior & post-earnings drift

Over the last eight reported quarters CRL has beaten consensus EPS estimates every time, for a beat rate of 8/8 (100%). The average earnings surprise across that stretch is 9.2%, which is a high and consistent number by most standards. Yet the average five-day price move after those reports is -1.37%, classified as a downward post-earnings drift. That combination—reliable beats but lackluster forward price performance—is the textbook profile of a stock where the market's real expectation has already run ahead of the published estimate.

The most recent four quarters illustrate the divergence. The August 5, 2026 report delivered a 9% surprise, a +1.84% next-day move, and a 0% move over the following five days. The May 7, 2026 quarter produced a 5.1% surprise but the stock fell -2.23% the next day and -12.42% over the next five sessions. The February 18, 2026 report had only a 2.6% surprise yet rallied +3.95% the next day and +6.05% over five days. The November 5, 2025 quarter, with a 4.7% surprise, saw +1.9% the next day and +2.27% over five days. With the next report scheduled for November 4, 2026 before the open and consensus EPS at $3.05, traders will again be weighing whether an eighth consecutive beat is already embedded in a stock that is up sharply from its 50-day EMA of $217.69 and technically overbought at an RSI of 76.2.

For a deeper dive into how sell-side analysts and institutional models are interpreting the November 4, 2026 report, review the full institutional verdict on CRL rather than relying on headline beats alone.